BusinessMyriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) TreatmentBy Nasdaq OMXApr 27, 2017, 11:05 AM UTC
BusinessWhite Paper Validates Re-entry Programs as a Powerful Solution to Increasing Diversity and Closing the Gender Gap in STEMBy Nasdaq OMXApr 26, 2017, 1:02 PM UTC
BusinessWhite Paper Validates Re-entry Programs as a Powerful Solution to Increasing Diversity and Closing the Gender Gap in STEMBy Nasdaq OMXApr 26, 2017, 1:01 PM UTC
BusinessIntegra LifeSciences Reports First Quarter 2017 Financial ResultsBy Nasdaq OMXApr 26, 2017, 10:00 AM UTC
BusinessMyriad to Announce Fiscal Third-Quarter 2017 Financial Results on May 2, 2017By Nasdaq OMXApr 18, 2017, 8:05 PM UTC
BusinessStudy Finds Wide Gap in Quality of BRCA1/2 Variant Classification Between Myriad Genetics and A Common Public DatabaseBy Nasdaq OMXApr 17, 2017, 11:05 AM UTC
BusinessEarth Science Tech, Inc. Targets Breast Cancer and Other Women's Health Issues in New Cannabis CBD-Based Pharmaceutical Drug Development InitiativesBy Nasdaq OMXApr 11, 2017, 11:45 AM UTC
